• CD28 targeting
  • How it works
AACR-2023 NI-2901 (CD47xPD-L1) & NI-3201 (CD28xPD-L1) bispecific antibodies

AACR-2023 NI-2901 (CD47xPD-L1) & NI-3201 (CD28xPD-L1) bispecific antibodies

AACR Annual Meeting 2023 - Walter Ferlin & Xavier Chauchet -


The American Association for Cancer Research (AACR), the largest cancer research organization, will host its Annual Meeting April 14-19, 2023. Light Chain Bioscience is very pleased to have Walter Ferlin and Xavier Chauchet attend in-person.

Walter Ferlin (CSO) and Xavier Chauchet (Project Leader) will be presenting posters (#2951 & #2973), describing our bispecific antibodies, NI-2901 (CD47xPD-L1) and NI-3201 (CD28xPD-L1).

aa

“NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade” will be exposed and presented on April 17 between 1:30 p.m -5:00 p.m. | section 23

Read poster - Poster #2951/29 [PDF]: 

aacr 2023 ni 2901 cd47xpd l1 bispecific antibodies scan

“NI-3201, a PD-L1xCD28 bispecific antibody for immune checkpoint-dependent CD28 co-stimulation” will be exposed and presented on April 17 between 1:30 p.m -5:00 p.m.| section 24

Read poster - Poster #2973/20 [PDF]: 

aacr 2023 ni 3201 checkpoint dependent cd28 costimulation scan 2


Ernest N. Morial Convention Center New Orleans, Louisiana

900 Convention Center Blvd, New Orleans, LA 70130, United States

Back to News

New publication in ImmunoTherapy of Cancer

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies

Read more

LinkedIn